FDA Brief

Warning letters Drugs

FDA warning letter to

Guangzhou Huli Technology Co., Ltd. dba Fantasy Face

MediumIssued Mar 31Posted Apr 7Center for Drug Evaluation and Research (CDER)

FDA warned Guangzhou Huli Technology (dba Fantasy Face) for selling an unapproved GLP-1 weight loss drug online.

What happened

FDA reviewed the company's eBay store, fantasyface, in December 2025 and found it offering "Googeer GLP-1 Weight Control Oral Solution" for sale in the United States. FDA said the product's labeling claims, such as weight management, blood sugar balance and body shaping, make it a drug, and that it is a new drug without an approved application. No inspection was reported.

What FDA found

  1. The product is a drug because its labeling claims it treats or affects the body, such as weight management and blood sugar balance.

    Section 201(g)(1) of the FD&C Act, 21 U.S.C. 321(g)(1)
  2. The product is a new drug because it is not generally recognized as safe and effective for its labeled uses.

    Section 201(p) of the FD&C Act, 21 U.S.C. 321(p)
  3. The product is an unapproved new drug because no FDA-approved application is in effect for it.

    Section 505(a) of the FD&C Act, 21 U.S.C. 355(a)
  4. Selling and shipping this unapproved drug across state lines is prohibited.

    Sections 301(d) and 505(a) of the FD&C Act, 21 U.S.C. 331(d) and 355(a)

What FDA wants

FDA asks the company to write within 15 working days describing the steps taken to correct the violations and prevent them from recurring, with supporting documents, or to explain why it believes the product is not in violation. The response goes to CDER's Office of Unapproved Drugs and Labeling Compliance by email, with the firm name and identifier 722228 in the subject line.

Who should pay attention

  • online sellers and marketplaces listing weight-loss or GLP-1 products
  • firms making drug-like claims for supplements or oral solutions
  • brands and importers sourcing weight-management products

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Natuzem

    FDA warned Mexico-based Natuzem for selling unapproved new drugs, including Reumofan Plus, to U.S. consumers online.

    High risk
  2. RonanRx, Inc. dba RonanRx

    FDA says RonanRx's website and X posts misbrand compounded semaglutide and tirzepatide with false or misleading claims.

    Low
  3. Calibrate IV Hydration

    FDA told Calibrate IV Hydration its umbilical cord and exosome IV products are unapproved drugs and unlicensed biologics.

    High risk
  4. Best Chinese Medicines LLC

    FDA warned Best Chinese Medicines LLC that five herbal products sold online are unapproved new drugs because their labeling claims to treat diseases.

    High risk